Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 80.00M | $ 2.81M | $ 6.34M | $ 19.16M | $ 8.82M |
| Gross Profit | $ 78.41M | $ 2.81M | $ 3.93M | $ 16.65M | $ 6.44M |
| Operating Income | $ -21.90M | $ -110.66M | $ -112.56M | $ -81.05M | $ -71.61M |
| EBITDA | $ -18.24M | $ -108.49M | $ -109.72M | $ -78.54M | $ -69.23M |
| Net Income | $ -9.72M | $ -97.33M | $ -105.62M | $ -78.33M | $ -68.44M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 241.02M | $ 236.22M | $ 202.92M | $ 218.16M | $ 112.91M |
| Total Assets | $ 260.72M | $ 257.69M | $ 226.69M | $ 235.00M | $ 129.58M |
| Total Debt | $ 8.63M | $ 10.82M | $ 13.42M | $ 0.00 | $ 17.00K |
| Net Debt | $ -49.58M | $ -14.74M | $ -21.68M | $ -35.41M | $ -57.03M |
| Total Liabilities | $ 17.68M | $ 22.50M | $ 27.74M | $ 23.46M | $ 34.40M |
| Stockholders' Equity | $ 243.03M | $ 235.19M | $ 198.94M | $ 211.54M | $ 95.18M |
| Cash Flow | |||||
| Free Cash Flow | $ -2.50M | $ -91.47M | $ -99.01M | $ -80.19M | $ -55.00M |
| Operating Cash Flow | $ -2.22M | $ -90.97M | $ -97.05M | $ -78.48M | $ -53.66M |
| Investing Cash Flow | $ 32.23M | $ -36.69M | $ 12.41M | $ -129.67M | $ -57.14M |
| Financing Cash Flow | $ 2.75M | $ 118.12M | $ 84.32M | $ 186.51M | $ 71.13M |